Mosanna Therapeutics
Last verified 2026-05-05. JSON
The funding figures on this page are attributed, not sourced: a publisher is on record but no document URL is. How we mark provenance.
| Total raised | $80.0Mattributed |
|---|---|
| Latest round | series-a, $80.0M, 2025-06-01attributed |
| Founded | 2023 |
| Headquarters | Basel Switzerland |
| Industry | bio |
| Stage | series-a |
| Website | mosanna.com |
Mosanna Therapeutics is building a nasal-spray drug for obstructive sleep apnea that reactivates upper-airway muscles during sleep instead of forcing the airway open mechanically. It targets the millions of OSA patients who reject or fail CPAP. The pharmacological approach restores a natural reflex rather than competing on mask comfort.
Funding rounds
| Date | Round | Amount | Lead |
|---|---|---|---|
| 2025-06-01 | series-a | $80.0M | undisclosed |
Detected tech stack
WordPress 7.0, Apache HTTP Server, MonsterInsights 10.2.0, Yoast SEO 27.6, Google Analytics, Google Tag Manager, Slider Revolution, jQuery Migrate 3.4.1, PHP, DoubleClick Floodlight, MySQL, jquery 3.
Provenance
| Fact | Status | Basis |
|---|---|---|
| Series A, $80.0M | attributed | crunchbase named as publisher. No document URL on file. |
| Total raised $80.0M | attributed | crunchbase named as publisher. No document URL on file. |
| Company existence | self-reported | mosanna.com, read 2026-05-05 |
| Description | self-reported | mosanna.com, read 2026-05-05 |
Nothing on this page is sourced yet. A sourced fact links to a document that states it.
Change history
No change recorded since records began on 2026-09-24.